2022年11月12日

加利福尼亚州帕洛阿尔托(BUSINESS WIRE) - #biotech - Medable Inc.是行业领先的以患者为中心的临床试验技术平台，今天宣布连续第二年被Everest Group评为“去中心化临床试验产品PEAK矩阵®评估2022”的领导者。该报告评估了来自24家公司的分散式临床试验(DCT)产品的远景、能力和市场影响力。Medable在领导者象限中排名最高，在视野、能力和市场影响力方面得分最高。这一认可强调了Medable在向dct转变的行业中的领导地位。自2020年以来，Medable已在60个国家通过300多项分散和混合临床试验部署了其软件即服务平台，为全球100多万人提供服务。通过最大限度地减少现场访问的需求，Medable客户取得了前所未有的成果——包括注册速度加快了200%，成本降低了50%。事实上，塔夫茨药物开发研究中心的一项新研究表明，平均而言，dct在II期和III期试验中可以实现5到13倍的净财务效益，分别相当于大约1000万美元和3900万美元的ROI。Medable首席执行官兼联合创始人米歇尔·朗迈尔(Michelle Longmire)表示:“我们连续第二年被珠穆朗玛峰集团评为领导者，感到非常自豪。”“临床研究的未来将由患者优先的方法来进行试验- Medable准备为生命科学公司提供可扩展的企业SaaS平台，解锁他们在整个投资组合中成功所需的工具。我们将继续引领，使试验更容易获得，更有效，更能代表所有人群，使有效的治疗方法更快地到达患者手中。” Everest Group’s PEAK Matrix® Assessment is based on two dimensions and multiple criteria: Market impact: Measures impact in the market via market adoption (number of clients, revenue base, year-over-year growth), portfolio mix (diversity of client base) and value delivered to clients based on customer feedback and other measures. Vision and capability: Measures ability to deliver products successfully via five sub-dimensions, including vision and strategy; technology capability; flexibility and ease of deployment; engagement and commercial model; and support. Medable stands out from competitors based on the following strengths: End-to-end, unified, and modular solution combining technology and services; Highly rated product quality and user experience from patients, sites, and sponsors; Extensive partnership network that includes leaders in systems integration, technology, data, direct-to-patient concierge, remote sites, and retail pharmacies; Quick and responsive client feedback and support services; Scalable solutions, as evidenced by various enterprise-level deals, including GSK ; and Digital certifications ( Medable Academy ) empowering professionals to design and build DCT studies on the Medable platform, increasing DCT adoption at research sites. The company has also made major strides since last year’s assessment – a $304 million fundraising round , expansion into Europe, a milestone pharmacy collaboration with CVS Health , making CNBC’s inaugural list of Top 2022 Startups for the Enterprise, plus new product offerings for patient consent , and oncology and vaccine trials. “Our strategy at Medable is to lead the industry with a proven, evidence-based platform that focuses on improving the patient’s journey,” said MaryAnne Rizk, Ph.D, Chief Strategy Officer at Medable. “As life sciences organizations are moving toward enterprise DCT platform adoption, the ability to scale with flexibility through an ecosystem of partners is fundamental to deliver transformational outcomes.” About Medable Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience and outcomes. Medable’s software has been named a Leader in the industry by both Everest Group and IDC. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Contacts +1 (610) 420-3413